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As CD44 is involved in the activation, proliferation, adhesion,
and extravasation of lymphocytes, we hypothesized that
CD44 could be involved in the pathogenesis of acute
renal allograft rejection. Renal biopsies and plasma were
collected from patients suffering an episode of acute
renal allograft rejection. CD44 and its ligands, hyaluronic acid
(HA) and osteopontin, were analyzed retrospectively by
immunohistochemistry and, computer-aided, morphometric
analysis. Soluble CD44 (sCD44) and osteopontin in the
plasma were determined by enzyme-linked immunosorbent
assay. During acute rejection episodes, CD44 and its ligands,
HA and osteopontin, were upregulated in the renal allograft.
Also, increased sCD44 plasma levels were observed, which
correlated with both tubular expression of CD44 and the
extent of infiltrate. No differences could be detected between
the different pathologic grades of rejection. Upregulation of
tubular CD44 and increased levels of circulating sCD44 may
reflect a common pathogenic mechanism during acute renal
rejection and could be useful markers in the diagnosis of
acute renal rejection.
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Despite the introduction of successful immunosuppressive
drug therapies, acute renal allograft rejection still occurs in
10–20% of patients after cadaveric renal transplantation
and causes graft loss in up to 6% in the first year after
transplantation.1 Essentially, acute rejection is an inflamma-
tory condition that is characterized by infiltration of T cells
into tubular epithelium and, as type and severity of rejection
change, also in vascular endothelium.2 Unravelling the
plethora of mechanisms at play could enhance early
recognition of allograft rejection and development of early
rejection markers, which might result in improved treatment
and reduction of the number of graft losses.
CD44 is a family of type I transmembrane glycoproteins
with a wide tissue distribution, including expression on
leukocytes, epithelial, and endothelial cells. CD44 has been
implicated in many physiological and pathological processes,
such as cell–cell and cell–matrix interaction, leukocyte
extravasation, wound healing/scarring, cell migration, lym-
phocyte activation, and binding/presentation of growth
factors.3–6 All CD44 isoforms contain a binding site for
hyaluronic acid (HA) and osteopontin, which are the major
ligands of CD44.4,7 Little is known about the physiological
role of CD44 and its ligands in the kidney. Under normal
conditions, CD44 and its ligands are hardly expressed in the
kidney, but upon injury, their expression is markedly
enhanced. CD44 can be detected in glomeruli, on renal
tubular epithelial cells (TECs), and capillary endothelial cells,
as documented in both human renal diseases8–10 and in
several animal models11–15 of renal injury.
HA, one of the major ligands of CD44, is a glycosamino-
glycan of the extracellular matrix, which is normally
expressed at low levels in the kidney. In renal disease,
synthesis of high molecular weight HA is increased.16
Consequently, HA markedly accumulates in the renal cortex
and may undergo degradation into low molecular weight
products,12,17 which exert proinflammatory effects.18,19 Lack
of CD44 is associated with persistent accumulation of HA
fragments at the site of injury.11,20 Interaction of CD44 on
T-lymphocytes with HA on endothelial cells plays an essen-
tial role in the extravasation of lymphocytes at sites of
inflammation21 and extravasation through the upregulation
of intercellular adhesion molecule-1 and vascular cellular
adhesion molecule-1 on various cells.22–24 These mechanisms
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are likely to be involved in the development of allograft
rejection. Indeed, anti-CD44 antibodies are capable of down-
modulating host reactivity in skin transplantation.25 In
accordance, systemic administration of low molecular weight
HA leads to prolonged renal allograft survival in rats by
blocking CD44–HA interaction.26
Osteopontin, the second major ligand of CD44, is a
secreted phosphoprotein, which is expressed on many
epithelial cell surfaces including the nephron. Osteopontin is
a potent chemoattractant for mononuclear cells and its
upregulation on proximal TECs is associated with monocyte/
macrophage infiltration.27,28 Osteopontin expression increases
rapidly upon renal injury.11,29,30 In addition, osteopontin may
also exert renoprotective actions by decreasing renal cell
apoptosis and participating in the regeneration of TECs.27,28,31
In the current study, we determined the simultaneous
renal expression of CD44 and its major ligands and the
release of CD44 and osteopontin into the circulation during
acute renal allograft rejection.
RESULTS
Patients
Patients and healthy individuals. Immunosuppressive drug
therapy consisted of prednisolone, cyclosporine, and myco-
phenolate mofetil. Owing to the retrospective design of this
study, part of the patients received induction treatment with
CD25 monoclonal antibody (basiliximab). As summarized
in Table 1, patients suffering acute rejection type 1 were
statistically significant and younger than the patients in the
other groups. Mean plasma creatinine values at the time of
biopsy were significantly higher in rejectors compared to
non-rejectors. No statistical differences were detected for all
other parameters examined. All kidney biopsies were scored
according to the Banff ’97 classification.2 Scores are summar-
ized in Table 2.
CD44 expression. To determine the expression of CD44
in acute renal allograft rejection, kidney biopsies were stained
by immunohistochemistry. Representative micrographs of
CD44 staining are shown in Figure 1. The extent of positive
staining of tubules, inflammatory cells, glomerular, and
vascular endothelium was scored in a semiquantitative
manner (Figure 2). CD44 expression in the non-rejecting
kidneys was predominantly located in the interstitial area and
on peritubular capillary endothelial cells (Figure 1). Baso-
lateral CD44 expression on tubular epithelium was very low
in non-rejecting kidneys (Figure 2a). Tubular expression of
CD44 (as indicated by white arrows) in the biopsies with
acute rejection types 1, 2, and 3 was significantly increased
compared to the biopsies of non-rejecting patients. However,
no statistically significant differences could be detected
between the different types of rejection (Figure 2a). No
significant correlation was observed between the Banff scores
for tubulitis or interstitial inflammation and CD44 staining
of tubuli (data not shown).
Table 1 | Clinical parameters of the included patients
No rejection AR type 1 AR type 2 AR type 3
No. patients (M/F) 9 (6/3) 10 (7/3) 7 (4/3) 6 (3/3)
Age in years (mean7s.d.) 52.0710.1 34.4713.8* 47.5710.7 54.0714.2
Donor characteristics
Age in years (mean7s.d.) 48.7711.2 31.6720.6 38.2715.3a 48.4715.6a
Cadaveric 7 7 0400 hours 6
Living related 2 3 0200 hours 0
Serum creatinine at the time of biopsy (mmol/l) (mean7s.d.) 175.47108.7 579.37429.5** 446.17210.5** 620.97307.0**
Drug regimen
P 9/9 10/10 7/7 6/6
C 9/9 10/10 7/7 6/6
MMF 4/9 3/10 5/7 3/6
A 1/9 2/10 2/7 2/6
B 9/9 3/10 3/7 3/6
HLA mismatch (mean7s.d.)
HLA-A 0.6270.52 1.0070.47 1.1470.38 0.8370.41
HLA-B 1.0070.0 0.8070.42 1.2970.49 0.8270.43
HLA-DR 0.5070.53 0.8070.79 1.0070.58 0.8370.75
ABO blood group incompatibility 3/9 2/10 2/7 1/6
Delayed graft function 5/9 3/10 3/7 2/6
Years on dialysis (mean7s.d.) 2.7971.67 4.0173.28 3.2672.10 3.2272.68
A: azathioprin; AR, androgen; B: basiliximab; C: cyclosporine; F, female; HLA, human lymphocyte antigen; M, male; MMF: mycophenolate mofetil; P: prednison; s.d., standard
deviation.
*The mean recipient age in this group was significantly lower compared to the non-rejectors and the AR type 3 group, Po0.05 determined by analysis of variance, followed
by a Bonferroni post hoc test.
**The mean serum creatinine at the time of biopsy was significantly increased in rejecting patients compared to the non-rejectors, Po0.05 determined by analysis of variance,
followed by a Bonferroni post hoc test.
aThe characteristics of one donor from this group were unknown.
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The mononuclear infiltrate in the biopsies with acute renal
rejection revealed strong membranous expression of CD44.
As expected, in the biopsies of non-rejecting patients hardly
any infiltrate was present (Figures 1 and 2b). In the biopsies
of rejecting allografts, infiltrate occupied a large area of the
interstitium (Figures 1 and 2b).
Moreover, tubular CD44 staining correlated very strongly
to the staining intensity of the infiltrate (Figure 2e). No
significant correlation was observed between the Banff scores
for tubulitis or interstitial inflammation and CD44 staining
of the infiltrate (data not shown).
Glomerular endothelium stained positively in many
biopsies including non-rejecting patients (Figure 1). With
respect to glomerular staining of CD44, no differences were
observed between the non-rejecting group and any of the
rejector groups (Figure 2c).
In addition to glomerular and peritubular capillaries, most
of the larger vessels showed positive staining for CD44. No
differences were detected between the non-rejecting group
Table 2 | Histological characteristics of the biopsies
No rejection Type 1 Type 2 Type 3
No. Glomeruli (mean7s.d.) 1878 1076 15710 1376
Scorea 0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3
Tubulitis 9 0 0 0 0 4 3 3 0 4 2 1 0 3 1 2
Interstitial inflammation 9 0 0 0 0 7 3 0 0 2 2 3 0 3 3 0
Glomerulitis 9 0 0 0 8 1 1 0 6 1 0 0 2 4 0 0
Arteriolar hyaline thickening 9 0 0 0 10 0 0 0 6 1 0 0 6 0 0 0
Intimal arteritis 9 0 0 0 9 1 0 0 0 5 1 1 0 0 0 6
Allograft glomerulopathy 7 2 0 0 10 0 0 0 7 0 0 0 6 0 0 0
Interstitial fibrosis 7 2 0 0 9 1 0 0 7 0 0 0 5 1 0 0
Tubular atrophy 9 0 0 0 8 2 0 0 5 2 0 0 6 0 0 0
Intimal thickening 9 0 0 0 9 1 0 0 6 1 0 0 6 0 0 0
Mesangial matrix increase 8 1 0 0 9 1 0 0 7 0 0 0 6 0 0 0
s.d., standard deviation.
aKidney biopsies were scored according to the Banff classification for acute rejection.2
No rejection Acute rejection type I
Acute rejection type II Acute rejection type III
Figure 1 | CD44-expression is increased during acute renal
allograft rejection. Renal biopsies of patients during allograft
rejection and non-rejecting biopsies were immunohistochemically
stained for CD44. In non-rejecting biopsies, interstitial cells and
capillary endothelial cells express CD44. During renal rejection, CD44
is also detected on infiltrating cells, vascular endothelium (black
arrow), and TECs (white arrow).
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Figure 2 | Increased tubular CD44 during acute renal allograft
rejection. Semiquantitative scoring of renal biopsies revealed
statistically significantly increased tubular CD44 (a) expression and
infiltrate (b) in biopsies of renal allografts during acute rejection.
No differences were observed in the expression of (c) glomerular-
or (d) vascular endothelial CD44. *Po0.05; **Po0.01; ***Po0.001
as determined by Kruskall–Wallis test. Tubular CD44 expression
correlated to CD44 expressed by the (e) infiltrate, (r¼ 0.70,
Po0.0001) as determined by a Spearman rho test.
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and any of the rejecting groups (Figure 2d). CD44 staining in
the extra control (chronic allograft nephropathy (CAN) and
post-reperfusion) biopsies was comparable to the staining
pattern of the non-rejectors (data not shown), except for a
significant upregulation of CD44 expression on vascular
endothelium in the post-reperfusion biopsies (not shown).
Expression of HA and osteopontin. HA was determined in
the cortical area. The expression of HA was detected
exclusively in the interstitial area in all biopsies (Figure 3a),
including non-rejecting allografts. Allograft biopsies of
type 1 rejection contained statistically significant increased
levels of HA (Figure 3a) compared to non-rejecting patients.
The allografts showing types 2 and 3 rejection contained
comparable levels of HA as the non-rejecting allografts. No
significant correlation was observed between the Banff scores
for tubulitis or interstitial inflammation and HA staining
(data not shown).
Non-rejecting allografts showed the expression of osteo-
pontin, but expression was limited to maximum 10% of
tubuli. In 17 out of 23 biopsies of the rejecting allografts,
tubular expression of osteopontin was increased in the cortex
(Figure 3b) compared to non-rejecting biopsies. Osteopontin
expression was generally observed in dilated tubuli. No
statistically significant differences between different rejection
types were observed. No significant correlation was observed
between the Banff scores for tubulitis or interstitial
inflammation and osteopontin staining (data not shown).
Stainings for HA and osteopontin in the extra control
(CAN and post-reperfusion) biopsies was comparable to the
staining pattern of the non-rejectors (data not shown), except
for a significant upregulation of HA staining in the CAN and
post-reperfusion biopsies (not shown).
Soluble CD44 and osteopontin in renal rejection. As
proteolytic activation (e.g., in inflammation) leads to shedd-
ing of CD44 from the cell surface, we determined soluble
CD44 (sCD44) in plasma. Patients suffering rejection had
increased sCD44 levels in plasma compared to non-rejecting
patients (Figure 4a). However, no differences in plasma
sCD44 could be detected in patient groups with different
types of rejection. sCD44 levels in non-rejecting patients
were comparable to plasma levels of healthy volunteers. CAN
patients showed elevated plasma levels of sCD44 when
compared to healthy individuals (Po0.05), although the
levels that were encountered in CAN patients are lower than
those of the rejection patients (Po0.001) (data not shown).
sCD44 levels correlated only very weakly to plasma creatinine
levels (Figure 5a).
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Figure 3 | Expression of the CD44 ligands osteopontin and HA.
(a) HA stained area was determined by digital image analysis. All
transplant biopsies stained positive for HA. In acute rejection type I,
renal HA is upregulated. Representative micrographs of HA staining
in biopsies of non-rejecting patients or patients with acute rejection
type I are shown next to the graph. (b) Immunohistochemical
staining of renal biopsies revealed osteopontin expression in 17
of 23 patients with acute rejection. No staining was observed in
transplant patients without acute allograft rejection. Representative
micrographs of osteopontin staining in biopsies of non-rejecting
patients or patients with acute rejection type I are shown next to
the graph. *Po0.05 as determined by Kruskall–Wallis test.
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Figure 4 | Increased sCD44 levels during acute renal allograft
rejection. (a) sCD44 levels in the plasma were determined by
enzyme-linked immunosorbent assay. Non-rejectors and healthy
volunteers had comparable sCD44 levels. sCD44 was increased in
patients suffering rejection. No statistically significant differences
were observed between different types of rejection. (b) Soluble
osteopontin levels were increased in transplant patients without
acute rejection compared to healthy volunteers. No differences were
observed in the transplanted patients. *Po0.05; **Po0.01 as
determined by Kruskall–Wallis test.
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Plasma osteopontin levels were significantly increased in
non-rejecting patients (Figure 4b) compared to healthy
volunteers. No differences could be detected in the rejecting
patients compared either to non-rejecting patients or healthy
volunteers.
sCD44 levels correlate with tubular expression of CD44. In-
terestingly, sCD44 correlated very strongly to tubular CD44
expression (Figure 5b) and to infiltrate CD44 expression
(Figure 5c). In contrast, sCD44 was inversely correlated to the
expression of CD44 on glomerular endothelium (Figure 5d).
No correlation was detected between sCD44 and vascular
expression of CD44 (Figure 5e).
No correlation was found between tubular expression of
osteopontin and soluble osteopontin in the plasma (r¼ 0.21,
P40.39).
DISCUSSION
The incidence of acute renal allograft rejection has decrea-
sed owing to successful immunosuppressive drugs. Yet, still
10–20% of transplanted patients suffer episodes of acute
renal allograft rejection.1 Although in recent years the
complex mechanisms that underlie mobilization of lympho-
cytes to the allograft have been unravelled to a certain extent,
knowledge of this issue remains incomplete.
Experimental evidence suggests a role for CD44 in
allograft rejection. In a model of renal allograft rejection in
rats, administration of low molecular weight HA prolonged
renal allograft survival by blocking CD44–HA interaction.26
In addition, anti-CD44 antibodies downmodulated host
reactivity in skin transplantation.25 These data strongly
suggest that HA–CD44 interactions contribute to allograft
rejection.
In the present study, we observed a strong upregulation
of CD44 in biopsies of rejected kidneys compared to non-
rejected kidneys, although no statistically significant differ-
ences were observed between different histological types of
rejection. This is in agreement with the data of Sarioglu
et al.32 Although Sarioglu et al.32 observed a correlation
between tubular CD44 expression and creatinine values at the
time of biopsy, we were unable to confirm this finding.
In the normal kidney, CD44 expression is restricted to
non-renal cells, for example, passenger leukocytes. In vitro,
proinflammatory cytokines such as tumor necrosis factor-a,
interferon-g, and interleukin-1b are able to induce CD44
expression on TECs and endothelial cells.13 As high levels of
these cytokines are presented during rejection, it is likely that
these proinflammatory cytokines are involved in de novo
expression of CD44 during rejection. It remains unclear what
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Figure 5 | Correlation between sCD44 and tubular CD44. sCD44 levels in plasma correlate to (a) creatinine levels in acute renal rejection.
sCD44 correlates to (b) tubular expression of CD44 and (c) CD44 expressed by infiltrating cells in biopsies of acute renal allograft rejection.
sCD44 is inversely correlated to CD44 expressed by (d) glomerular endothelium but not to (e) vascular endothelium. Correlation was
determined using a Spearman rho test.
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the pathophysiological role of CD44 on TECs is. A possible
role may be found in the adhesion of lymphocytes according
to a comparable mechanism found in CD103/E–cadherin
ligation. In renal allograft rejection, CD8 positive cells
upregulate CD103 upon TGF-b stimulation, which enables
them to bind to tubular E-cadherin.33 Tubular expression of
CD44 in the presence of HA fragments may cause anchorage
of lymphocytes to TECs in a CD44-dependent manner. These
mechanisms may elongate the period that the lymphocytes
exert their deleterious effects in the renal allograft. Previously,
we showed that expression of CD44 on TECs leads to the
enhancement of TGF-b signalling and subsequently accele-
rates development of fibrosis.11 This may be associated with
the development of late fibrosis in the allograft.
Although in normal kidneys CD44 is not detectable,9,13
we found strong positive staining for CD44 of the endo-
thelium in biopsies of non-rejecting allografts. This finding
suggests ongoing activation of endothelial cells, despite
the absence of overt signs of acute rejection or ischemia–
reperfusion injury. Although additional studies are required
to elucidate the mechanism at play, this unexpected finding
may (with other factors) be involved in the development
of CAN.
HA is a glycosaminoglycan of the extracellular matrix,
which markedly accumulates in the renal cortex upon injury
and may undergo degradation into low molecular weight
products.12,17 CD44 interactions with low molecular weight
HA products lead to proinflammatory effects.18,19,22 HA is
not expressed in normal renal tissue. After transplantation,
we observed accumulation of HA in the interstitial area in all
biopsies, including non-rejecting transplants, with increase in
type 1 rejection. As more proteolytic and other degrading
enzyme activity is expected in severe inflammation, HA
expression in types 2 and 3 rejection may be decreased. HA is
an important part of the connective tissue and is capable of
water regulation. Excessive accumulation of HA in interstitial
tissue retains water and contributes to the development of
interstitial tissue edema.34,35 This may lead to decreased graft
function and graft survival potentially via induction of
CAN; however, further research is required to confirm this
hypothesis.
Osteopontin, one of the major ligands of CD44, promotes
accumulation of macrophages, decreases renal cell apoptosis,
and participates in the regeneration of TECs upon renal
injury.27,28 In non-rejecting biopsies, osteopontin was
expressed in 10% or less of cortical tubuli. In contrast, more
than 75% of the rejecting allografts expressed osteopontin.
This is in agreement with a previous study by Alchi et al.,29
who found that expression of osteopontin in proximal tubuli
in non-rejecting allografts was weak or absent. However, in
rejecting allografts, osteopontin expression was upregulated
on proximal tubular epithelium in up to 50% of the tubules.
Osteopontin expression positively correlated with the degree
of interstitial inflammation and TEC proliferation, suggesting
that inducible expression of osteopontin in the tubular
epithelium may have a pathogenic role in acute renal allograft
rejection by mediating interstitial monocyte infiltration and
possibly tubular regeneration.29
Plasma sCD44 in patients suffering rejection was increased
compared to non-rejecting patients, but independent of the
histological type of rejection. We observed a moderate
correlation between sCD44 levels and serum creatinine
(r¼ 0.40, Po0.05). Increased plasma sCD44 levels have been
described in immune activation, for example, in primary
Sjo¨grens’ syndrome36 and in malignancies,37,38 whereas low
plasma sCD44 levels are found in immunodeficiency.39
sCD44 positively correlated to tubular CD44 expression
and expression of CD44 by the mononuclear infiltrate,
suggesting tubular epithelium and inflammatory cells as a
possible source for sCD44. The remaining intracellular CD44
domain that remains after intramembranous CD44 cleavage
is translocated to the nucleus inducing transcriptional
activity,40 leading to the upregulation of CD44 mRNA. This
results in a high turnover of CD44 molecules, which was
proposed to be essential in efficient cell migration.41 This
may explain the correlation observed between sCD44 and the
cellular infiltrate.
CD44 may be released through nonspecific shedding after
increased proteolytic activity. The released extracellular
domain of the receptor competes with cell surface CD44
for ligand binding. However, the patho-physiological role of
sCD44 is still poorly understood. In an in vivo model of
mammary carcinoma, overexpression of sCD44 was able to
block HA binding to membrane-bound CD44 and was able
to antagonize the effects of this interaction, thereby
promoting apoptosis, inhibiting MMP-mediated invasion,
and inhibiting tumour cell proliferation.42
Altogether, our findings suggest an important role for
CD44 and its interaction with HA and osteopontin in renal
allograft rejection. However, more research is required to
precisely understand the role of this receptor–ligand(s)
complex and the contribution to renal allograft dysfunction.
MATERIALS AND METHODS
Patients and healthy individuals
Twenty-three patients with biopsy-proven acute renal allograft
rejection were selected randomly from the patient population of the
Academic Medical Center of the University of Amsterdam. The
histological type of rejection was graded according to the Banff ’97
classification2 (type 1, 10 patients; type 2, seven patients; type 3, six
patients). As control, nine transplant patients without clinical or
histopathological evidence of acute or chronic allograft rejection
were included. The nine non-rejecting patients underwent protocol
graft biopsy 6 months after renal transplantation. As additional
control served renal biopsies and plasma from six patients with
biopsy-proven CAN and six renal transplant biopsies that were
obtained immediately after reperfusion (data not shown). The
protocol had been approved by the Medical Ethical Committee of
the Academic Medical Center of the University of Amsterdam, each
patient had given written informed consent. Plasma samples from
both rejectors and non-rejectors were collected at the time of biopsy,
before initiation of antirejection treatment. Plasma samples of 10
healthy volunteers were included as control.
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Enzyme-linked immunosorbent assays
Plasma sCD44 (Bender Medsystems, Vienna, Austria) and osteo-
pontin (Assay design, Ann Arbor, MI, USA) were determined by
enzyme-linked immunosorbent assay according to the manufac-
turer’s instructions.
Immunohistochemistry
Immunohistochemical studies were performed on formalin-fixed,
paraffin-embedded sections. After deparaffinization, endogenous
peroxidase activity was blocked with 0.3% H2O2 in methanol. Free
protein binding sites were blocked with 10% normal goat serum.
Antigen retrieval for CD44 and osteopontin was performed by
microwave treatment (10 mM sodium citrate, pH 6). For immuno-
staining of CD44, sections were incubated with Hermes-3, which
is directed against a constant part of the human CD44 molecule43
(kindly provided by Dr S Jalkanen, MediCity Research Laboratory,
Turku University, Turku, Finland). Osteopontin was detected
using anti-osteopontin (clone 10A16, IBL-Hamburg, Hamburg,
Germany). HA was detected as described previously.11 As a negative
control, we used species- and isotype-matched antibodies. After
incubation with the secondary (horseradish peroxidase-labelled)
antibody or streptavidin (DAKO, Glostrup, Denmark), bound
antibodies were visualized by developing peroxidase activity using
3,3-diamino-benzidine tetrachloride (Sigma, St Louis, MO, USA).
Slides were counterstained with methyl green.
Histopathological scoring
In the scoring procedure, the cortical area was analyzed with the
exclusion of sub-capsular areas (0.5 mm). Tubular, glomerular
endothelium, and vascular endothelium CD44 was graded on a
scale of 1–4: 1¼ less than 10%; 2¼ 10–25%; 3¼ 25–50%; and
4¼more than 50% of the tubules/glomerular endothelium/vascular
endothelium stained positive for CD44. Arbitrary scores were given
to the CD44 staining of the interstitial infiltrate according to the
following criteria: 0¼ no CD44-positive inflammatory infiltrate;
1¼ less than 10% of the interstitial area; 2¼ 10–25%; 3¼ 25–50%;
and 4¼more than 50% of the interstitial area.
Osteopontin was graded according to the percentage of tubuli
positive for osteopontin: 1¼ 0–10% of the tubuli; 2¼ 10–20%;
3¼ 20–30%; and 4¼more than 30% of the tubuli stained positive
for osteopontin.
Expression of interstitial HA was analyzed using a digital image
analysis program (Image pro-plus, Mediacybernetics, Germany),
results are expressed as a percentage of the analyzed cortex.11
Statistical analysis
Serum CD44 and osteopontin were analyzed by analysis of variance
followed by a Bonferroni post hoc test. Histological data were
analyzed by Kruskall–Wallis analysis. The degree of correlation was
determined using the Spearman test.
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